Pravinkumar Darji honored with “International Achiever’s Award” at the 38th Asian Business Leadership Summit and Awards Thailand.
In June 2024, Pravinkumar Darji was honored with the “International Achiever’s Award ” for Excellence in Pharma Innovation in acknowledgement of Exceptional contribution to pharmaceutical research and manufacturing, making lasting impact of excellence on the global pharmaceutical economy.
Mr. Darji has worked as a researcher for more than 14 years at well-known pharmaceutical companies such as Exemplify Biopharma Inc., Aavis Pharmaceuticals, Torrent Pharmaceuticals ltd., India, and Zydus Lifescience Limited. India. He has successfully created new technology that stops drug abuse while working on research and development projects. The urgent need to fight the opioid problem, a major public health issue in the United States, makes Mr. Darji’s work even more important.
His creative work on making formulations that make drugs less likely to be abused is a big step towards lowering the misuse and abuse of pharmaceutical drugs. Because opioid addiction and overdose have such bad effects and have hit crisis levels in the country, this work is even more important. Furthermore, Mr. Darji’s progress in creating new drug delivery methods, like the Single Layer Osmotic Controlled Release tablets, has big advantages in terms of how well drugs work and how well patients follow their treatment plans. This work also showed that it is possible to make a single-layer osmotic controlled release tablet that has a lot of medicine that doesn’t dissolve in water. These new ideas could change the way treatments are given and make health results better for many patients.
Mr. Darji’s creative SCOP tablet form, which lets low-soluble drugs be released slowly. Mr. Darji’s well-known status in the scientific community, pointing out that his groundbreaking work on things like Single Layer Osmotic Controlled Release tablets has had a big impact on scientists both in the area and around the world. Mr. Darji is the innovator to apply for two German patents, one for a liposomal formulation of Hydroxyurea that is a stable, injectable formulation designed to improve drug bioavailability while minimizing systemic toxicity and the other for an indole derivative-based formulation for targeted cancer treatment. These patents show how innovatively he has contributed to the development of targeted therapies. The excellent study that Mr. Darji did not only help the field of pharmaceutical grow, but it also helped the US economy grow.
